

# A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (TETON-2) // A Multinational, Uncontrolled, Usability Evaluation Study of the TD-300/A Tyvaso Inhalation Device Used in RIN-PF-303

Published: 11-10-2022

Last updated: 10-01-2025

This study has been transitioned to CTIS with ID 2024-514761-19-00 check the CTIS register for the current data. The primary objective of RIN-PF-303 is to evaluate superiority of inhaled treprostinil against placebo for the annual rate of change in...

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Recruitment started
<b>Health condition type</b>	Lower respiratory tract disorders (excl obstruction and infection)
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON56203

### Source

ToetsingOnline

### Brief title

RIN-PF-303 // RIN-PF304

### Condition

- Lower respiratory tract disorders (excl obstruction and infection)

**Synonym**

Interstitial Lung Disease (ILD), Lungfibrosis

**Research involving**

Human

**Sponsors and support**

**Primary sponsor:** United Therapeutics Corp.

**Source(s) of monetary or material Support:** Industry (United Therapeutics Corp)

**Intervention**

**Keyword:** IPF, RIN-PF-303 // RIN-PF304, Treprostinil, Tyvaso Inhalation Device

**Outcome measures****Primary outcome**

The primary endpoint of the study is the change in absolute FVC in subjects with IPF from baseline to Week 52.

Safety will be assessed by reviewing the following parameters:

- Adverse events (AEs) and serious adverse events (SAEs)
- Clinical laboratory parameters
- Vital signs, including saturation of peripheral capillary oxygenation (SpO2)
- 12-lead electrocardiograms (ECGs)

**Secondary outcome**

Secondary efficacy endpoints of the study are:

- Time to clinical worsening (including time to death, respiratory hospitalization, or  $\geq 10\%$  relative decline in % predicted FVC)
- Time to first acute exacerbation of IPF
- Overall survival at Week 52

- Change from baseline in % predicted FVC at Week 52
- Change from baseline in King's Brief Interstitial Lung Disease Questionnaire score at Week 52
- Change from baseline in diffusion capacity of lungs for carbon monoxide (DLCO) at Week 52

Exploratory efficacy endpoints of the study are:

- Change from baseline in absolute FVC at Weeks 16, 28, and 40
- Change from baseline in N-terminal pro-brain natriuretic peptide (NT-proBNP) at Week 52
- Change from baseline in resting supplemental oxygen use at Week 52

## Study description

### Background summary

Idiopathic Pulmonary Fibrosis (IPF) is a serious, chronic, progressive, fibrosing interstitial pneumonia with no known cause typically occurring in patients above 50 years of age. It is characterized by progressive fibrosis, lung scarring, and a typical radiological pattern. IPF is associated with increasing cough and dyspnea, greatly impacts patient quality of life, and eventually leads to death from respiratory failure or complicating comorbidities. Currently there is no cure for IPF, and only 2 drugs are approved to treat the condition (nintedanib and pirfenidone). (protocol 1.1) Treprostinil belongs to the group of prostacyclins and has a well-characterized pharmacology. treprostinil is approved for the treatment of pulmonary arterial hypertension (PAH) following the subcutaneous, intravenous, inhaled (as treprostinil sodium), or oral (as treprostinil diolamine) routes of administration. (protocol 1.2.1) The improvements in FVC and reduced exacerbations of underlying lung disease from the INCREASE study (RCT), combined with the preclinical evidence of antifibrotic activity of treprostinil, suggest that inhaled treprostinil may offer a treatment option for patients with IPF. (protocol 1.3) This study hypothesizes that inhaled treprostinil will have a positive effect

on absolute FVC after 52 weeks of therapy as compared with placebo when administered to subjects with IPF. (protocol 1.4)

## **Study objective**

This study has been transitioned to CTIS with ID 2024-514761-19-00 check the CTIS register for the current data.

The primary objective of RIN-PF-303 is to evaluate superiority of inhaled treprostinil against placebo for the annual rate of change in absolute forced vital capacity (FVC) from baseline to Week 52.

## **Study design**

This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, efficacy and safety study of subjects with IPF treated with inhaled treprostinil over a 52-week period.

## **Intervention**

Daily treatment during 52 weeks with inhaled treprostinil or placebo using the TD-300 ultrasonic nebulizer.

## **Study burden and risks**

Treprostinil has a long history of safety and efficacy in WHO Group 1 PAH and is currently marketed as 3 formulations (parenteral solution, inhalation solution, and oral tablet) in various regions. Additionally, the recently completed INCREASE study (RIN-PH-201) demonstrated that inhaled treprostinil is safe and efficacious for the treatment of PH-ILD. The pulmonary function test safety results from INCREASE suggest that inhaled treprostinil may provide substantial benefit with minimal risks for the treatment of IPF.

The TD-300/A has been in use since 01 May 2018. Use of the TD-300/A has resulted in no occasional, probable, or frequent severe ADEs. A further analysis of the anticipated ADEs resulting from the risk mitigation processes, which incorporate the TD-300/A post-market use, can be found in the TD-300/A IB. The potential benefits of the nebulised treprostinil solution administered with the TD-300/A in IPF subjects discussed previously, and the minimal observed risk of the TD-300/A after more than 4 million exposure days, suggest the TD-300/A provides substantial benefit with minimal risks for the treatment of IPF.

## Contacts

### Scientific

United Therapeutics Corp.  
P. Smith  
Alexander Drive 55 Tw  
Durham 27709-0152  
United States  
+1 9194255431

### Public

United Therapeutics Corp.  
RP Regulatory Department  
Alexander Drive 55 Tw  
Durham 27709-0152  
United States  
+19194255431

## Trial sites

### Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)  
Elderly (65 years and older)

### Inclusion criteria

Eligible subjects must be  $\geq 40$  years of age at the time of signing informed consent; have a diagnosis of IPF based on the 2018 ATS/ERS/JRS/ALAT Clinical Practice Guideline (Raghu 2018) and confirmed by central review of high-resolution computed tomography imaging and if available, surgical lung biopsy; and have a FVC  $\geq 45\%$  predicted. Subjects on pirfenidone or nintedanib must be on a stable and optimized dose for  $\geq 30$  days prior to Baseline.

## Exclusion criteria

Subjects with forced expiratory volume in 1 second (FEV1)/FVC <0.70, those on >10 L/min of supplemental oxygen at rest at Baseline, and women who are pregnant or lactating will not be eligible to participate in the study.

## Study design

### Design

Study phase:	3
Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo
Primary purpose:	Treatment

### Recruitment

NL	
Recruitment status:	Recruitment started
Start date (anticipated):	16-06-2023
Enrollment:	16
Duration:	13 months (per patient)
Type:	Actual

### Medical products/devices used

Product type:	Medical device
Generic name:	TD-300 Tyvaso Inhalation system
Registration:	No
Product type:	Medicine
Brand name:	Tyvaso inhalation solution
Generic name:	treprostinil for inhalation

## Ethics review

Approved WMO

Date: 11-10-2022

Application type: First submission

Review commission: MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Approved WMO

Date: 13-02-2023

Application type: First submission

Review commission: MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Approved WMO

Date: 26-05-2023

Application type: Amendment

Review commission: MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Approved WMO

Date: 06-06-2023

Application type: Amendment

Review commission: MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Approved WMO

Date: 06-09-2023

Application type: Amendment

Review commission: MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Approved WMO

Date: 20-11-2023

Application type: Amendment

Review commission: MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Approved WMO

Date: 12-12-2023

Application type: Amendment

Review commission: MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Approved WMO

Date:	14-02-2024
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO	
Date:	12-03-2024
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

Register	ID
CCMO	NL82375.100.22
EudraCT	2021-005881-17
EU-CTR	2024-514761-19-00
CCMO	NL82375.100.22